← All Haemonetics CORP filings

Haemonetics CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
HAE
Haemonetics CORP
10-K: Haemonetics Reports FY2026 Results, Navigates Market Shifts
Haemonetics Corporation's fiscal year 2026 annual report details a 2.0% decrease in net revenues to $1.33 billion, impacted by portfolio transitions, while the Hospital segment showed growth.
NYSE
HAE
Haemonetics CORP
10-K: Haemonetics Reports Fiscal 2025 Results, Driven by Hospital Segment Growth
Haemonetics Corporation's fiscal 2025 results show a 4.0% increase in net revenues, driven primarily by growth in the Hospital segment, while Plasma and Blood Center segments experienced declines.
NYSE
HAE
Haemonetics CORP
10-K: Haemonetics Reports Fiscal Year 2024 Results, Focuses on Growth and Efficiency
Haemonetics' fiscal year 2024 shows revenue growth driven by Plasma and Hospital segments, alongside strategic initiatives to manage costs and expand in key markets.